Comparative effectiveness of metronidazole and vancomycin for treatment of Clostridioides difficile infection in hospitalized children

被引:0
|
作者
Sandora, Thomas J. [1 ,2 ]
Savage, Timothy J. [1 ,2 ,3 ]
Ryan, Morgan E. [4 ]
Dahlberg, Suzanne E. [2 ,4 ,5 ]
Daugherty, Kaitlyn [2 ,6 ]
Kelly, Ciaran P. [2 ,6 ]
Pollock, Nira R. [2 ,7 ,8 ]
Kociolek, Larry K. [9 ,10 ]
机构
[1] Boston Childrens Hosp, Dept Pediat, Div Infect Dis, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA
[4] Boston Childrens Hosp, Biostat Res & Design Ctr, Boston, MA USA
[5] Boston Childrens Hosp, Dept Pediat, Div Pulm Med, Boston, MA USA
[6] Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA USA
[7] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA USA
[8] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA
[9] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Div Infect Dis, Chicago, IL USA
[10] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
基金
美国国家卫生研究院;
关键词
HEALTH-CARE EPIDEMIOLOGY; DISEASES SOCIETY; AMERICA IDSA; GUIDELINES; MANAGEMENT; UPDATE;
D O I
10.1017/ash.2025.51
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To compare rates of clinical response in children with Clostridioides difficile infection (CDI) treated with metronidazole vs vancomycin.Design: Retrospective cohort study was performed as a secondary analysis of a previously established prospective cohort of hospitalized children with CDI. For 187 participants 2-17 years of age who were treated with metronidazole and/or vancomycin, the primary outcome of clinical response (defined as resolution of diarrhea within 5 days of treatment initiation) was identified retrospectively. Baseline variables associated with the primary outcome were included in a logistic regression propensity score model estimating the likelihood of receiving metronidazole vs vancomycin. Logistic regression using inverse probability of treatment weighting (IPTW) was used to estimate the effect of treatment on clinical response.Results: One hundred seven subjects received metronidazole and 80 subjects received vancomycin as primary treatment. There was no univariable association between treatment group and clinical response; 78.30% (N = 83) of the metronidazole treatment group and 78.75% (N = 63) of the vancomycin group achieved clinical response (P = 0.941). After adjustment using propensity scores with IPTW, the odds of a clinical response for participants who received metronidazole was 0.554 (95% CI: 0.272, 1.131) times the odds of those who received vancomycin (P = 0.105).Conclusions: In this observational cohort study of pediatric inpatients with CDI, the rate of resolution of diarrhea after 5 days of treatment did not differ among children who received metronidazole vs vancomycin.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] The Impact of Malnutrition on Patients Hospitalized With Clostridioides difficile Infection
    Fard, Darian
    Lee, Andy
    Reed, Austin
    Basida, Sanket D.
    Saad, Baraa
    Mansour, Mahmoud
    Ali, Ahmad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S167 - S167
  • [32] How to: Clostridioides difficile infection in children
    Krutova, Marcela
    de Meij, Tim G. J.
    Fitzpatrick, Fidelma
    Drew, Richard J.
    Wilcox, Mark H.
    Kuijper, Ed J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (08) : 1085 - 1090
  • [33] Oral Vancomycin Prophylaxis for Clostridioides difficile Infection: Cause or Effect?
    Hurley, James C.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : E2850 - E2851
  • [34] COST-EFFECTIVENESS OF FIDAXOMICIN VERSUS VANCOMYCIN AND METRONIDAZOLE IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION IN SPAIN
    Watt, M.
    de Nigris, E.
    McCrea, C.
    VALUE IN HEALTH, 2017, 20 (09) : A784 - A784
  • [35] Comparative Effectiveness of Vancomycin and Metronidazole for the Initial Episode of Nonsevere Clostridium Difficle Infection
    Baroiu, Liliana
    Beznea, Adrian
    Condratovici, Catalin Plesea
    Onisor, Cristian
    Grigore, Camelia Ana
    Topor, Gabi
    Rugina, Sorin
    REVISTA DE CHIMIE, 2019, 70 (10): : 3741 - 3745
  • [36] Ridinilazole for the treatment of Clostridioides difficile infection
    Carlson, Travis J.
    Endres, Bradley T.
    Basseres, Eugenie
    Gonzales-Luna, Anne J.
    Garey, Kevin W.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (04) : 303 - 310
  • [37] Higher mortality rates associated with Clostridioides difficile infection in hospitalized children with cystic fibrosis
    Santhanam, Prathipa
    Egberg, Matthew
    Kappelman, Michael D.
    PEDIATRIC PULMONOLOGY, 2023, 58 (02) : 484 - 491
  • [38] Risk of rehospitalization due to Clostridioides difficile infection among hospitalized patients with Clostridioides difficile: a cohort study
    Drwiega, Emily N.
    Johnson, Stuart
    Danziger, Larry H.
    Skinner, Andrew M.
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2024, 45 (11) : 1293 - 1299
  • [39] Update on Treatment of Clostridioides difficile Infection
    Cho, Janice M.
    Pardi, Darrell S.
    Khanna, Sahil
    MAYO CLINIC PROCEEDINGS, 2020, 95 (04) : 758 - 769
  • [40] Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile
    Turner, Nicholas A.
    Warren, Bobby G.
    Gergen-Teague, Maria F.
    Addison, Rachel M.
    Addison, Bechtler
    Rutala, William A.
    Weber, David J.
    Sexton, Daniel J.
    Anderson, Deverick J.
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (04) : 648 - 656